Table 1.
Endpoint | Rosuvastatin rates per 100 person-year | Placebo rates per 100 person-year | Relative risk reduction % | P value |
---|---|---|---|---|
JUPITER results | N = 8901 | N = 8901 | ||
Primary endpoint | 0.77 | 1.36 | 44 | <0.00001 |
Nonfatal MI | 0.12 | 0.33 | 65 | <0.00001 |
Nonfatal stroke | 0.16 | 0.31 | 48 | 0.003 |
Arterial revasc | 0.38 | 0.71 | 46 | <0.0001 |
MI, stroke, and CV death | 0.45 | 0.85 | 47 | <0.00001 |
Death from any cause | 1 | 1.25 | 20 | 0.02 |
AURORA results | N = 1389 | N = 1384 | ||
Primary endpoint | 9.2 | 9.5 | 4 | 0.59 |
Nonfatal MI | 2.1 | 2.5 | 16 | 0.23 |
Nonfatal stroke | 1.2 | 1.1 | NA | 0.42 |
Death from CV cause | 7.2 | 7.3 | 0 | 0.97 |
Death from any cause | 13.5 | 14 | 4 | 0.51 |
Death from non-CV causes | 5.5 | 6 | 8 | 0.34 |
Abbreviations: MI, myocardial infarction; revasc, revascularizations; CV, cardiovascular.